Boehringer Ingelheim receives rights to oral small molecules from Sitryx with potential applications in multiple autoimmune disorders. Depending on the progress of Boehringer’s research, Sitryx could receive more than $500 million.
The post Boehringer Boosts Pipeline, Adding Oral Small Molecules With Broad Immunology & Inflammation Potential appeared first on MedCity News.
